Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Lawyer for former top lawmaker in Michigan House expects he will be chargedChina unveils regulations on water conservationChinese FM meets with Vietnamese counterpartCompany believes it found sunken barge in Ohio River near Pittsburgh, one of 26 that got looseOlivia Williams opens up on 'harrowing' experience as guest star on season four finale of FriendsChina condemns attack on Iranian embassy in SyriaIMF: Outlook for world economy is brighter, though still modest by historical standardsEarly voting for S. Korea's parliamentary elections kicks offChina exercises veto power in UN Security Council to uphold international justice: envoyHamas says 19 killed in Israeli shelling near Gaza City, Israel denies
2.7504s , 6500.6484375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gaze news portal